| First Author | Baumann J | Year | 2022 |
| Journal | Sci Adv | Volume | 8 |
| Issue | 20 | Pages | eabn2627 |
| PubMed ID | 35584211 | Mgi Jnum | J:328695 |
| Mgi Id | MGI:7284511 | Doi | 10.1126/sciadv.abn2627 |
| Citation | Baumann J, et al. (2022) Reduced platelet forces underlie impaired hemostasis in mouse models of MYH9-related disease. Sci Adv 8(20):eabn2627 |
| abstractText | MYH9-related disease patients with mutations in the contractile protein nonmuscle myosin heavy chain IIA display, among others, macrothrombocytopenia and a mild-to-moderate bleeding tendency. In this study, we used three mouse lines, each with one point mutation in the Myh9 gene at positions 702, 1424, or 1841, to investigate mechanisms underlying the increased bleeding risk. Agonist-induced activation of Myh9 mutant platelets was comparable to controls. However, myosin light chain phosphorylation after activation was reduced in mutant platelets, which displayed altered biophysical characteristics and generated lower adhesion, interaction, and traction forces. Treatment with tranexamic acid restored clot retraction in the presence of tPA and reduced bleeding. We verified our findings from the mutant mice with platelets from patients with the respective mutation. These data suggest that reduced platelet forces lead to an increased bleeding tendency in patients with MYH9-related disease, and treatment with tranexamic acid can improve the hemostatic function. |
